Examining the melanocortin receptor agonist peptide developed for pigmentation and photoprotection research.
MT-2, also known as Melanotan II, is a synthetic cyclic heptapeptide analog of alpha-melanocyte stimulating hormone (α-MSH). Originally developed at the University of Arizona during the late 1980s and early 1990s, MT-2 was designed to mimic the activity of the endogenous α-MSH hormone, which plays a central role in regulating melanin production in the skin. Unlike its linear precursor, MT-2 features a cyclic structure that confers enhanced metabolic stability and receptor binding affinity, making it a valuable tool for melanocortin pathway research.
As a non-selective melanocortin receptor agonist, MT-2 interacts with multiple receptor subtypes within the melanocortin system. This broad receptor activity has made it one of the most widely studied peptides in dermatological and endocrine research, with a substantial body of preclinical literature exploring its effects on pigmentation, energy homeostasis, and related signaling cascades.
The development of MT-2 arose from efforts by researchers at the University of Arizona to create a potent, stable analog of α-MSH that could be used to study melanogenesis — the biological process by which melanocytes produce melanin pigment. Early studies demonstrated that MT-2 could stimulate melanin synthesis in cell culture models and in vivo animal systems, establishing it as a key pharmacological tool for understanding skin pigmentation at the molecular level.
Subsequent research expanded the scope of MT-2 investigation beyond melanogenesis. Because the melanocortin receptor family (MC1R through MC5R) is distributed across numerous tissues, preclinical studies have examined the peptide's activity in models related to energy balance, feeding behavior, and cardiovascular function. MC1R activation remains the primary focus of pigmentation research, while MC4R engagement has drawn interest in metabolic and neuroendocrine studies. The peptide's ability to activate multiple receptor subtypes simultaneously has provided researchers with a unique tool for dissecting the complex interplay among melanocortin signaling pathways.
Photoprotection research represents another significant area of investigation. Preclinical models have explored whether melanocortin-driven increases in eumelanin production may confer protective effects against ultraviolet radiation-induced DNA damage. These studies have contributed to a broader understanding of the skin's endogenous defense mechanisms and the role that melanocortin signaling plays in maintaining genomic integrity in UV-exposed tissues.
MT-2 is a cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. It has a molecular weight of approximately 1,024 Da. The cyclic structure is formed through a lactam bridge between the aspartic acid and lysine side chains, which constrains the peptide backbone into a conformation that favors high-affinity binding to melanocortin receptors. The inclusion of norleucine (Nle) at the N-terminus and a D-phenylalanine (D-Phe) residue within the ring enhances both receptor potency and resistance to enzymatic degradation.
The acetylated N-terminus and amidated C-terminus further protect the peptide from exopeptidase cleavage, contributing to its stability in biological environments. These structural modifications collectively distinguish MT-2 from the endogenous α-MSH tridecapeptide and account for its improved pharmacological profile in research settings. The peptide is supplied as a white to off-white lyophilized powder that is readily soluble in sterile water or bacteriostatic water for reconstitution.
MT-2 is utilized across a diverse range of preclinical research domains. In melanogenesis studies, researchers use the peptide to activate MC1R signaling in melanocyte cell lines and animal models, enabling detailed investigation of the cAMP/PKA/MITF pathway that governs melanin biosynthesis. These experiments help elucidate the molecular switches controlling eumelanin versus pheomelanin production ratios.
Melanocortin receptor signaling research employs MT-2 as a reference agonist for characterizing receptor binding kinetics, downstream second messenger cascades, and receptor desensitization profiles across the MC1R–MC5R family. Its non-selective nature makes it particularly useful in comparative pharmacology studies where researchers evaluate subtype-specific responses to a common agonist stimulus.
Photoprotection and UV damage research leverages MT-2 to study the relationship between induced pigmentation and resistance to ultraviolet-mediated cellular injury. Additional applications include skin pigmentation pathway mapping, investigation of melanocortin involvement in inflammatory modulation, and structure-activity relationship studies where MT-2 serves as a structural template for designing next-generation selective melanocortin receptor ligands.
Lyophilized MT-2 should be stored at -20°C for long-term preservation, where it maintains stability for up to 24 months when kept sealed and dry. Once reconstituted with bacteriostatic water or sterile water, the solution should be refrigerated at 2-8°C and used within 30 days. MT-2 is light-sensitive; protect both the lyophilized powder and reconstituted solution from direct light exposure by storing in amber vials or wrapping vials in aluminum foil. Avoid repeated freeze-thaw cycles, as these can compromise peptide integrity. Always handle with appropriate laboratory gloves and use sterile technique during reconstitution to prevent microbial contamination.
This product is sold exclusively for laboratory and scientific research purposes. It is not intended for human or veterinary use, diagnostic purposes, or therapeutic applications. All research must comply with applicable laws and institutional guidelines. By purchasing, you confirm you are a qualified researcher. Please review our full legal disclaimer.